Compare GITS & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GITS | CLGN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | South Korea | Israel |
| Employees | 5 | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.0M |
| IPO Year | N/A | 2015 |
| Metric | GITS | CLGN |
|---|---|---|
| Price | $1.54 | $0.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 145.4K | 78.2K |
| Earning Date | 05-19-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.27 |
| 52 Week High | $7.09 | $3.23 |
| Indicator | GITS | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 29.81 |
| Support Level | $1.49 | $0.27 |
| Resistance Level | $2.83 | $0.45 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 2.38 | 11.88 |
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.